NFE2L2 and non-small cell lung carcinoma: Signaling pathway analysis indicated that ruthenium(II) complexes can be developed as efficient nuclear factor erythroid 2-related factor 2 (Nrf2) inhibitors and can overcome the Cisplatin resistance in a highly metastatic and aggressive subtype—non-small-cell lung cancer (NSCLC).